 |
|
Pimecrolimus and Tacrolimus for the Treatment of Intertriginous and Facial Psoriasis
Are They Effective?
Michael Bigby, MD
Arch Dermatol. 2005;141:1152-1153.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Commentary 1 on: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Gribetz C, Ling M, Lebwohl M, et al
J Am Acad Dermatol. 2004;51:731-738.
Question 1: What is the response of intertriginous psoriasis to topical pimecrolimus in comparison with vehicle?
Design: Randomized, participant- and outcome-evaluator–masked, vehicle-controlled trial.
Setting: Industry-sponsored, multicenter study of patients recruited from medical school and hospital departments of dermatology.
Patients: Adult patients with inverse psoriasis.
Intervention: Twice-daily application of 1% pimecrolimus cream or vehicle.
Main Outcome Measure: Percentage of patients reaching an investigator global assessment score of 0 (clear) or 1 (almost clear: mild erythema, no scaling, and no induration) by week 8 of treatment. A secondary outcome measure was the percentage of patients reaching a patient self-assessment score of 0 (complete disease control) or 1 (good disease control) by week 8 of treatment.
Results: At week . . . [Full Text of this Article] Comment
Comment
AUTHOR INFORMATION
Department of Dermatology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Mass
RELATED ARTICLE
Proven Efficacy of Tacrolimus for Facial and Intertriginous Psoriasis
Mark Lebwohl, Amy Freeman, M. Shane Chapman, Steven Feldman, Jennifer Hartle, and Alice Henning
Arch Dermatol. 2005;141(9):1154.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Proven Efficacy of Tacrolimus for Facial and Intertriginous Psoriasis
Lebwohl et al.
Arch Dermatol 2005;141:1154-1154.
FULL TEXT
|
